Literature DB >> 2785953

Tolerance to aggregated human IgG but not ovalbumin can be induced by concurrent administration of depleting or non-depleting anti-L3T4 monoclonal antibodies.

B Charlton1, T E Mandel.   

Abstract

Tolerance to soluble antigens has previously been shown to occur in mice if anti-L3T4 monoclonal antibody (MoAb) is administered at the time of antigen exposure. The process of tolerance induction may require the depletion of L3T4+ cells or it may be due to down-regulation or negative signalling of L3T4+ cells. We compared the effects of L3T4+ cell depletion and L3T4 antigen blockade at the time of primary antigen challenge on long-term humoral responses. Anti-L3T4 MoAb GK1.5 (IgG2b) and H129.19 (IgG2a) were used to deplete or block, respectively, L3T4+ cells. Following a short course of MoAb and antigen challenge with both aggregated human IgG (ag-HGG) and ovalbumin (OVA) in each mouse, primary response titres to each antigen in both MoAb treated groups were approximately 1:10(2) compared with approximately 1:10(5) in control mice. Repeated antigen challenge significantly increased the anti-OVA titre in both MoAb treated groups and by 150 days they were similar to controls. However, anti-HGG titres did not increase significantly in either of the MoAb treated groups. Thus either depletion of peripheral L3T4+ cells, or blockade of the L3T4 antigen without depletion of peripheral L3T4+ cells, can invoke a state of long-term antigen-specific tolerance to some antigens. Why the effect is restricted to particular antigens, and the exact mechanisms of tolerance induction remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785953     DOI: 10.1038/icb.1989.1

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  1 in total

1.  Prevention of Th2-mediated murine allergic airways disease by soluble antigen administration in the neonate.

Authors:  S P Hogan; P S Foster; B Charlton; R M Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.